alpha(v)beta(3) Antagonists based on a central thiophene scaffold.

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Biochemistry

Background:

• Integrin alpha(v)beta(3) plays a crucial role in various physiological processes, including bone resorption.
• Development of selective antagonists for alpha(v)beta(3) is a therapeutic target for conditions like osteoporosis.
• Arg-mimetic compounds are essential for designing effective integrin antagonists.

Purpose of the Study:

• To design and synthesize novel thiophene-based alpha(v)beta(3) antagonists.
• To evaluate the potency and selectivity of these antagonists against alpha(v)beta(3) and alpha(IIb)beta(3) integrins.
• To assess the in vivo efficacy of a lead compound in an osteoporosis model.

Main Methods:

• Synthesis of a series of thiophene derivatives incorporating an acylguanidine moiety.
• In vitro assays to measure inhibition of alpha(v)beta(3) mediated cell adhesion.
• Evaluation of binding affinity and selectivity against alpha(IIb)beta(3).
• In vivo testing of compound 19 in the TPTX model of osteoporosis.

Main Results:

• Several novel, potent alpha(v)beta(3) antagonists were identified.
• Structural modifications, including guanidine type and side chains, influenced potency and selectivity.
• Compound 19 demonstrated significant activity in the TPTX model, suggesting therapeutic potential for osteoporosis.
• Exploration of cyclic vs. open guanidines and various side chains provided structure-activity relationship insights.

Conclusions:

• The described thiophene-based acylguanidines are effective alpha(v)beta(3) antagonists.
• Compound 19 shows promise as a therapeutic agent for osteoporosis.
• Further development of these antagonists could lead to new treatments for bone diseases.